BioScience Health Innovations, Inc (BHIC) Fair Value & Analysis
Healthcare · US · Market cap $47.7M
BioScience Health Innovations, Inc
BHIC · US
Fair value as of: Jul 14, 2026
From 20 valuation models · updated 27 days ago
Share price −2.9% over the past month.
A solid business, but screening 76% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($1.20). The favourable scenario is already priced in.
- Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range ($0.5600 to $1.20) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 14, 2026.
How to read this chart
60‑month range $0.0002 – $52.00 · fair‑value band $0.5600 – $1.20 · the $4.00 price screens above the $0.9600 fair value. Dashed = 300-day average. As of Jul 14, 2026.
Analysis
BioScience Health Innovations, Inc (BHIC) currently trades at $4.00, while our model-based Fair Value estimate is $0.9600, implying the stock looks roughly 76.0% overvalued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, BioScience Health Innovations, Inc generated revenue of $5.2M at a net margin of -0.3%. Revenue declined 38.8% year over year. It earns a return on equity of -1.0%. The stock trades on a trailing P/E of 139.3. Fundamentals as of Jul 14, 2026
Our scenario range runs from $0.5600 (bear case) to $1.20 (bull case); at $4.00, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -76%, BHIC screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 20 models by family
Widest divergence: Growth Earnings ($2.54) versus Asset-Based ($0.0900). Highest evidence: Growth DCF (72).
Notify me when BHIC reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 14, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 65 · Market factors (momentum, volatility) 29
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
BioScience Health Innovations, Inc. operates as a health and wellness innovation company focuses on mitochondrial health science, advanced peptide delivery, and metabolic care in the United States.
Full company description
BioScience Health Innovations, Inc. operates as a health and wellness innovation company focuses on mitochondrial health science, advanced peptide delivery, and metabolic care in the United States. It offers nutritional supplements, peptides, and bioactive compounds through its core technology Mineral Oxide Delivery System, as well as provides Oracle NetSuite, an accounting and financial reporting system. The company also provides services, including testosterone and hormonal Optimization, NAD+ and cellular health, and platform licensing and peptide delivery. It sells its products through Amazon platform; and direct-to-consumer. The company was formerly known as Nowtransit Inc and changed its name to BioScience Health Innovations, Inc. in February 2025. BioScience Health Innovations, Inc. is based in Bluffdale, Utah.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
BioScience Health Innovations, Inc reported revenue of $5.7M in FY2025 versus $69.3K in FY2022, a compound +334.5%/yr. Reported net income was $642K in FY2025.
BHIC screens 76% overvalued. Compare with JD Health International Inc →
Peer Group
Pharmaceutical Retailers · 61 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 14, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$39.20 | HK$33.28 | -15% |
| Raia Drogasil S.A RADL3 | R$18.20 | R$15.58 | -14% |
| Yifeng Pharmacy Chain Co 603939 | ¥20.24 | ¥29.07 | +44% |
| DaShenLin Pharmaceutical Group 603233 | ¥17.81 | ¥23.86 | +34% |
| Corporativo Fragua, S.A. FRAGUAB | 463.00 MXN | 821.18 MXN | +77% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥11.51 | ¥10.57 | -8% |
| MedPlus Health Services Limited MEDPLUS | ₹690.20 | ₹379.25 | -45% |
| Yixintang Pharmaceutical Group 002727 | ¥11.46 | ¥9.45 | -18% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥14.40 | ¥10.05 | -30% |
| Apotea AB APOTEA | kr 74.75 | kr 43.95 | -41% |
Compare BioScience Health Innovations, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is BioScience Health Innovations, Inc (BHIC) overvalued or undervalued?
What is the fair value of BHIC?
What is the quality score of BHIC?
What is the revenue of BioScience Health Innovations, Inc (BHIC)?
What is the net profit margin of BHIC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track BioScience Health Innovations, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.